Brii Biosciences
PublicBrii Biosciences is now publicly traded
The data on this page reflects Brii Biosciences's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jul 13, 2021
Last Round
Series C
Mar 23, 2021
Est. Valuation at Exit
$1.5B
Total Funding Raised
$905.4M
Company Overview
Brii Biosciences is a biotechnology company that develops therapies for infectious diseases and central nervous system disorders.
Sector
Biotech
AI Layer
Application
Keywords
Brii Biosciences Comparables
Compare Brii Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shanghai Ark Biopharmaceutical Co., Ltd. | 64% | |
| Argo Biopharma | 49% | |
| EIT Pharma | 48% |
For institutional investors. Book with your work email.
Brii Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Jul 13, 2021 | ||||
| Series C | Mar 23, 2021 | ||||
| Series B | Dec 27, 2019 | ||||
| Series A | May 24, 2018 |
For institutional investors. Book with your work email.
Brii Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boyu Capital | Series A, IPO, Series B |
| Invesco Ltd. | IPO |
| Lake Bleu Capital | Series C |
| OppenheimerFunds | Series C |
| RBC Global Asset Management (Asia) Limited | IPO |
| Blue Pool Capital | Series A, Series B |
| The Valliance Fund | IPO |
For institutional investors. Book with your work email.
Brii Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.